Minghui Pharmaceutical and ASKA Pharmaceutical Enter into Exclusive License Agreement for the IGF-1R Antibody in Japan

The Quick Take
HANGZHOU, China, SHANGHAI and TOKYO, Nov. 4, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan. MHB018A...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Pearson and Westermann collaborate to help learners in Germany build the English language skills they need to succeed in study and work
Schools will be able to give learners access to Pearson Test of English (PTE) Academic and Versant assessments from January 2027 BERLIN, Nov. 4, 2026…
Business
AppGate ZTNA Now Available on the CrowdStrike Marketplace
NEW YORK & BARCELONA, Spain--(BUSINESS WIRE)--Fal.Con Europe 2026 -- AppGate, a leader in Zero Trust Network Access (ZTNA) for enterprise IT, OT and AI, today…
Business
CrowdStrike Extends the Agentic SOC to Detect and Stop the Agent Insider Threat
AUSTIN, Texas & BARCELONA, Spain--(BUSINESS WIRE)--Fal.Con Europe 2026 -- CrowdStrike (NASDAQ: CRWD) today introduced agentic SOC innovations to detect the new…
Business
